Insmed traded at $162.43 this Thursday April 2nd, decreasing $2.43 or 1.47 percent since the previous trading session. Looking back, over the last four weeks, Insmed lost 10.50 percent. Over the last 12 months, its price rose by 121.51 percent. Looking ahead, we forecast Insmed to be priced at 157.54 by the end of this quarter and at 143.74 in one year, according to Trading Economics global macro models projections and analysts expectations.
Insmed Incorporated is a global biopharmaceutical company. The Company's product, ARIKAYCE (amikacin liposome inhalation suspension) is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which the Company is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases. TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which offers a differentiated product profile for pulmonary arterial hypertension (PAH) and other rare pulmonary disorders.